At a glance
- Originator Gilead Sciences
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 12 Jun 2001 No-Development-Reported for HIV infections treatment in USA (PO)
- 14 Sep 1998 Profile reviewed
- 13 Sep 1996 New profile